{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascularization%2C+Pathologic&page=4",
    "query": {
      "condition": "Neovascularization, Pathologic",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 197,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascularization%2C+Pathologic&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascularization%2C+Pathologic&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T23:32:54.926Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02308215",
      "title": "Retinal Therapy Guided by 3D OCT Image Analysis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Michael Abramoff",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "45 Years to 120 Years"
      },
      "enrollment_count": 77,
      "start_date": "2010-07",
      "completion_date": "2018-07-05",
      "has_results": false,
      "last_update_posted_date": "2019-08-30",
      "last_synced_at": "2026-10-26T23:32:54.926Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02308215"
    },
    {
      "nct_id": "NCT03834753",
      "title": "A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age-related Macular Degeneration",
        "Neovascular Age-related Macular Degeneration",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Outlook Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 228,
      "start_date": "2019-06-25",
      "completion_date": "2021-07-08",
      "has_results": true,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-26T23:32:54.926Z",
      "location_count": 50,
      "location_summary": "Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03834753"
    },
    {
      "nct_id": "NCT03427476",
      "title": "CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "CTT1057",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cancer Targeted Technology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2018-01-01",
      "completion_date": "2018-08-31",
      "has_results": false,
      "last_update_posted_date": "2019-04-22",
      "last_synced_at": "2026-10-26T23:32:54.926Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03427476"
    },
    {
      "nct_id": "NCT01884597",
      "title": "Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "PCV",
        "Polypoidal Choroidal Vasculopathy"
      ],
      "interventions": [
        {
          "name": "high-dose ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hawaii Pacific Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "25 Years to 95 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-11",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-10-09",
      "last_synced_at": "2026-10-26T23:32:54.926Z",
      "location_count": 3,
      "location_summary": "Honolulu, Hawaii • ‘Aiea, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "‘Aiea",
          "state": "Hawaii"
        },
        {
          "city": "‘Aiea",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01884597"
    },
    {
      "nct_id": "NCT00559936",
      "title": "Topical Avastin for Treatment of Corneal Neovascularization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Topical Avastin 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2007-02",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2022-04-29",
      "last_synced_at": "2026-10-26T23:32:54.926Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00559936"
    },
    {
      "nct_id": "NCT02387957",
      "title": "A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Fovista®",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2016-04-26",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2024-10-30",
      "last_synced_at": "2026-10-26T23:32:54.926Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "New London",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02387957"
    },
    {
      "nct_id": "NCT02307682",
      "title": "Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Brolucizumab ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1775,
      "start_date": "2014-12-08",
      "completion_date": "2018-03-28",
      "has_results": true,
      "last_update_posted_date": "2025-01-16",
      "last_synced_at": "2026-10-26T23:32:54.926Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02307682"
    },
    {
      "nct_id": "NCT03953079",
      "title": "A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Drug: GB-102",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Graybug Vision",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2019-09-26",
      "completion_date": "2021-06-03",
      "has_results": true,
      "last_update_posted_date": "2022-01-19",
      "last_synced_at": "2026-10-26T23:32:54.926Z",
      "location_count": 33,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 28 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03953079"
    },
    {
      "nct_id": "NCT00071227",
      "title": "Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Degeneration",
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Triamcinolone Acetonide (TAC-PF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2003-10-15",
      "completion_date": "2007-08-15",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-26T23:32:54.926Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071227"
    },
    {
      "nct_id": "NCT00417846",
      "title": "Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Maculopathy, Age-Related",
        "Choroidal Neovascularization"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2007-01",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2009-10-05",
      "last_synced_at": "2026-10-26T23:32:54.926Z",
      "location_count": 4,
      "location_summary": "Beverly Hills, California • Baltimore, Maryland • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Beachwood",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00417846"
    }
  ]
}